United States Cytomegalovirus Therapeutics Market Report 2017

Publisher Name :
Date: 03-Apr-2017
No. of pages: 104
Inquire Before Buying

In this report, the United States Cytomegalovirus Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

- The West

- Southwest

- The Middle Atlantic

- New England

- The South

- The Midwest

with sales (volume), revenue (value), market share and growth rate of Cytomegalovirus Therapeutics in these regions, from 2012 to 2022 (forecast).

United States Cytomegalovirus Therapeutics market competition by top manufacturers/players, with Cytomegalovirus Therapeutics sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

- AbbVie

- Actavis

- Clinigen Group

- Merck

- Perrigo Company

- Roche

- Valeant Pharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

- Ganciclovir/Valganciclovir

- Foscarnet

- Cidofovir

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Cytomegalovirus Therapeutics for each application, including

- CMV Retinitis

- Pneumonia

- Gastrointestinal Ulcers

- Encephalitis

- Mouth Ulcers

- Pharyngitis

United States Cytomegalovirus Therapeutics Market Report 2017

Table of Contents
United States Cytomegalovirus Therapeutics Market Report 2017
1 Cytomegalovirus Therapeutics Overview
1.1 Product Overview and Scope of Cytomegalovirus Therapeutics
1.2 Classification of Cytomegalovirus Therapeutics by Product Category
1.2.1 United States Cytomegalovirus Therapeutics Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Cytomegalovirus Therapeutics Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Ganciclovir/Valganciclovir
1.2.4 Foscarnet
1.2.5 Cidofovir
1.3 United States Cytomegalovirus Therapeutics Market by Application/End Users
1.3.1 United States Cytomegalovirus Therapeutics Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 CMV Retinitis
1.3.3 Pneumonia
1.3.4 Gastrointestinal Ulcers
1.3.5 Encephalitis
1.3.6 Mouth Ulcers
1.3.7 Pharyngitis
1.4 United States Cytomegalovirus Therapeutics Market by Region
1.4.1 United States Cytomegalovirus Therapeutics Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Cytomegalovirus Therapeutics Status and Prospect (2012-2022)
1.4.3 Southwest Cytomegalovirus Therapeutics Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Cytomegalovirus Therapeutics Status and Prospect (2012-2022)
1.4.5 New England Cytomegalovirus Therapeutics Status and Prospect (2012-2022)
1.4.6 The South Cytomegalovirus Therapeutics Status and Prospect (2012-2022)
1.4.7 The Midwest Cytomegalovirus Therapeutics Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Cytomegalovirus Therapeutics (2012-2022)
1.5.1 United States Cytomegalovirus Therapeutics Sales and Growth Rate (2012-2022)
1.5.2 United States Cytomegalovirus Therapeutics Revenue and Growth Rate (2012-2022)
2 United States Cytomegalovirus Therapeutics Market Competition by Players/Suppliers
2.1 United States Cytomegalovirus Therapeutics Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Cytomegalovirus Therapeutics Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Cytomegalovirus Therapeutics Average Price by Players/Suppliers (2012-2017)
2.4 United States Cytomegalovirus Therapeutics Market Competitive Situation and Trends
2.4.1 United States Cytomegalovirus Therapeutics Market Concentration Rate
2.4.2 United States Cytomegalovirus Therapeutics Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Cytomegalovirus Therapeutics Manufacturing Base Distribution, Sales Area, Product Type
3 United States Cytomegalovirus Therapeutics Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Cytomegalovirus Therapeutics Sales and Market Share by Region (2012-2017)
3.2 United States Cytomegalovirus Therapeutics Revenue and Market Share by Region (2012-2017)
3.3 United States Cytomegalovirus Therapeutics Price by Region (2012-2017)
4 United States Cytomegalovirus Therapeutics Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Cytomegalovirus Therapeutics Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Cytomegalovirus Therapeutics Revenue and Market Share by Type (2012-2017)
4.3 United States Cytomegalovirus Therapeutics Price by Type (2012-2017)
4.4 United States Cytomegalovirus Therapeutics Sales Growth Rate by Type (2012-2017)
5 United States Cytomegalovirus Therapeutics Sales (Volume) by Application (2012-2017)
5.1 United States Cytomegalovirus Therapeutics Sales and Market Share by Application (2012-2017)
5.2 United States Cytomegalovirus Therapeutics Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Cytomegalovirus Therapeutics Players/Suppliers Profiles and Sales Data
6.1 AbbVie
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Cytomegalovirus Therapeutics Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 AbbVie Cytomegalovirus Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Actavis
6.2.2 Cytomegalovirus Therapeutics Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Actavis Cytomegalovirus Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Clinigen Group
6.3.2 Cytomegalovirus Therapeutics Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Clinigen Group Cytomegalovirus Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Merck
6.4.2 Cytomegalovirus Therapeutics Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Merck Cytomegalovirus Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Perrigo Company
6.5.2 Cytomegalovirus Therapeutics Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Perrigo Company Cytomegalovirus Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Roche
6.6.2 Cytomegalovirus Therapeutics Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Roche Cytomegalovirus Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Valeant Pharmaceuticals
6.7.2 Cytomegalovirus Therapeutics Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Valeant Pharmaceuticals Cytomegalovirus Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
7 Cytomegalovirus Therapeutics Manufacturing Cost Analysis
7.1 Cytomegalovirus Therapeutics Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Cytomegalovirus Therapeutics
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Cytomegalovirus Therapeutics Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Cytomegalovirus Therapeutics Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Cytomegalovirus Therapeutics Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Cytomegalovirus Therapeutics Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Cytomegalovirus Therapeutics Sales Volume Forecast by Type (2017-2022)
11.3 United States Cytomegalovirus Therapeutics Sales Volume Forecast by Application (2017-2022)
11.4 United States Cytomegalovirus Therapeutics Sales Volume Forecast by Region (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
List of Tables and Figures
Figure Product Picture of Cytomegalovirus Therapeutics
Figure United States Cytomegalovirus Therapeutics Market Size (K Pcs) by Type (2012-2022)
Figure United States Cytomegalovirus Therapeutics Sales Volume Market Share by Type (Product Category) in 2016
Figure Ganciclovir/Valganciclovir Product Picture
Figure Foscarnet Product Picture
Figure Cidofovir Product Picture
Figure United States Cytomegalovirus Therapeutics Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Cytomegalovirus Therapeutics by Application in 2016
Figure CMV Retinitis Examples
Figure Pneumonia Examples
Figure Gastrointestinal Ulcers Examples
Figure Encephalitis Examples
Figure Mouth Ulcers Examples
Figure Pharyngitis Examples
Figure United States Cytomegalovirus Therapeutics Market Size (Million USD) by Region (2012-2022)
Figure The West Cytomegalovirus Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Cytomegalovirus Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Cytomegalovirus Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Cytomegalovirus Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Cytomegalovirus Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Cytomegalovirus Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Cytomegalovirus Therapeutics Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Cytomegalovirus Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Cytomegalovirus Therapeutics Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Cytomegalovirus Therapeutics Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Cytomegalovirus Therapeutics Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Cytomegalovirus Therapeutics Sales Share by Players/Suppliers
Figure 2017 United States Cytomegalovirus Therapeutics Sales Share by Players/Suppliers
Figure United States Cytomegalovirus Therapeutics Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Cytomegalovirus Therapeutics Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Cytomegalovirus Therapeutics Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Cytomegalovirus Therapeutics Revenue Share by Players/Suppliers
Figure 2017 United States Cytomegalovirus Therapeutics Revenue Share by Players/Suppliers
Table United States Market Cytomegalovirus Therapeutics Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Cytomegalovirus Therapeutics Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Cytomegalovirus Therapeutics Market Share of Top 3 Players/Suppliers
Figure United States Cytomegalovirus Therapeutics Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Cytomegalovirus Therapeutics Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Cytomegalovirus Therapeutics Product Category
Table United States Cytomegalovirus Therapeutics Sales (K Pcs) by Region (2012-2017)
Table United States Cytomegalovirus Therapeutics Sales Share by Region (2012-2017)
Figure United States Cytomegalovirus Therapeutics Sales Share by Region (2012-2017)
Figure United States Cytomegalovirus Therapeutics Sales Market Share by Region in 2016
Table United States Cytomegalovirus Therapeutics Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Cytomegalovirus Therapeutics Revenue Share by Region (2012-2017)
Figure United States Cytomegalovirus Therapeutics Revenue Market Share by Region (2012-2017)
Figure United States Cytomegalovirus Therapeutics Revenue Market Share by Region in 2016
Table United States Cytomegalovirus Therapeutics Price (USD/Pcs) by Region (2012-2017)
Table United States Cytomegalovirus Therapeutics Sales (K Pcs) by Type (2012-2017)
Table United States Cytomegalovirus Therapeutics Sales Share by Type (2012-2017)
Figure United States Cytomegalovirus Therapeutics Sales Share by Type (2012-2017)
Figure United States Cytomegalovirus Therapeutics Sales Market Share by Type in 2016
Table United States Cytomegalovirus Therapeutics Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Cytomegalovirus Therapeutics Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Cytomegalovirus Therapeutics by Type (2012-2017)
Figure Revenue Market Share of Cytomegalovirus Therapeutics by Type in 2016
Table United States Cytomegalovirus Therapeutics Price (USD/Pcs) by Types (2012-2017)
Figure United States Cytomegalovirus Therapeutics Sales Growth Rate by Type (2012-2017)
Table United States Cytomegalovirus Therapeutics Sales (K Pcs) by Application (2012-2017)
Table United States Cytomegalovirus Therapeutics Sales Market Share by Application (2012-2017)
Figure United States Cytomegalovirus Therapeutics Sales Market Share by Application (2012-2017)
Figure United States Cytomegalovirus Therapeutics Sales Market Share by Application in 2016
Table United States Cytomegalovirus Therapeutics Sales Growth Rate by Application (2012-2017)
Figure United States Cytomegalovirus Therapeutics Sales Growth Rate by Application (2012-2017)
Table AbbVie Basic Information List
Table AbbVie Cytomegalovirus Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure AbbVie Cytomegalovirus Therapeutics Sales Growth Rate (2012-2017)
Figure AbbVie Cytomegalovirus Therapeutics Sales Market Share in United States (2012-2017)
Figure AbbVie Cytomegalovirus Therapeutics Revenue Market Share in United States (2012-2017)
Table Actavis Basic Information List
Table Actavis Cytomegalovirus Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Actavis Cytomegalovirus Therapeutics Sales Growth Rate (2012-2017)
Figure Actavis Cytomegalovirus Therapeutics Sales Market Share in United States (2012-2017)
Figure Actavis Cytomegalovirus Therapeutics Revenue Market Share in United States (2012-2017)
Table Clinigen Group Basic Information List
Table Clinigen Group Cytomegalovirus Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Clinigen Group Cytomegalovirus Therapeutics Sales Growth Rate (2012-2017)
Figure Clinigen Group Cytomegalovirus Therapeutics Sales Market Share in United States (2012-2017)
Figure Clinigen Group Cytomegalovirus Therapeutics Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck Cytomegalovirus Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Merck Cytomegalovirus Therapeutics Sales Growth Rate (2012-2017)
Figure Merck Cytomegalovirus Therapeutics Sales Market Share in United States (2012-2017)
Figure Merck Cytomegalovirus Therapeutics Revenue Market Share in United States (2012-2017)
Table Perrigo Company Basic Information List
Table Perrigo Company Cytomegalovirus Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Perrigo Company Cytomegalovirus Therapeutics Sales Growth Rate (2012-2017)
Figure Perrigo Company Cytomegalovirus Therapeutics Sales Market Share in United States (2012-2017)
Figure Perrigo Company Cytomegalovirus Therapeutics Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche Cytomegalovirus Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Roche Cytomegalovirus Therapeutics Sales Growth Rate (2012-2017)
Figure Roche Cytomegalovirus Therapeutics Sales Market Share in United States (2012-2017)
Figure Roche Cytomegalovirus Therapeutics Revenue Market Share in United States (2012-2017)
Table Valeant Pharmaceuticals Basic Information List
Table Valeant Pharmaceuticals Cytomegalovirus Therapeutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Valeant Pharmaceuticals Cytomegalovirus Therapeutics Sales Growth Rate (2012-2017)
Figure Valeant Pharmaceuticals Cytomegalovirus Therapeutics Sales Market Share in United States (2012-2017)
Figure Valeant Pharmaceuticals Cytomegalovirus Therapeutics Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Cytomegalovirus Therapeutics
Figure Manufacturing Process Analysis of Cytomegalovirus Therapeutics
Figure Cytomegalovirus Therapeutics Industrial Chain Analysis
Table Raw Materials Sources of Cytomegalovirus Therapeutics Major Players/Suppliers in 2016
Table Major Buyers of Cytomegalovirus Therapeutics
Table Distributors/Traders List
Figure United States Cytomegalovirus Therapeutics Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Cytomegalovirus Therapeutics Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Cytomegalovirus Therapeutics Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Cytomegalovirus Therapeutics Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Cytomegalovirus Therapeutics Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Cytomegalovirus Therapeutics Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Cytomegalovirus Therapeutics Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Cytomegalovirus Therapeutics Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Cytomegalovirus Therapeutics Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Cytomegalovirus Therapeutics Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Cytomegalovirus Therapeutics Sales Volume Share Forecast by Region (2017-2022)
Figure United States Cytomegalovirus Therapeutics Sales Volume Share Forecast by Region (2017-2022)
Figure United States Cytomegalovirus Therapeutics Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global Drugs For Herpes Labialis (Oral Herpes) Market Research Report 2018
    Published: 08-Jan-2018        Price: US 2900 Onwards        Pages: 118
    In this report, the global Drugs For Herpes Labialis (Oral Herpes) market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Drugs For Herpes Labialis (Oral Herpes) in these regions, from 2013 to 2025 (forecast), covering - North Ame......
  • Global Ampicillin Market Research Report 2011-2023
    Published: 08-Jan-2018        Price: US 1960 Onwards        Pages: 75
    Summary The global Ampicillin market will reach xxx Million USD in 2017 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as follows:......
  • Pertussis (Whooping Cough) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 92
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H2 2017, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape. Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antib......
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 38
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2017, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections (Infectious Disease) pipeline landscape. Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warm to the ......
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2017, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape. Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs). This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant......
  • Meningitis - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 53
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H2 2017, provides an overview of the Meningitis (Infectious Disease) pipeline landscape. "Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in pro......
  • Toxoplasmosis - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 44
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Pipeline Review, H2 2017, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape. Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalari......
  • Dengue Fever - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 166
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H2 2017, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape. Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It c......
  • Zika Virus Infections - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 183
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Pipeline Review, H2 2017, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape. Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include bein......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs